Articles

  • 3 days ago | tmj4.com | Jacob Gardenswartz |Tony Aria

    A series of new economic analyses released Wednesday, several conducted by the federal government using official data sources, point to slowing economic growth and increased consumer prices brought on by President Donald Trump’s trade war.

  • 2 weeks ago | scrippsnews.com | Jacob Gardenswartz

    President Donald Trump on Tuesday announced new details about his “Golden Dome” missile defense program, suggesting the sweeping effort to protect the United States from foreign attacks would be “fully operational” before the end of his term in 2029.

  • 3 weeks ago | katc.com | Jacob Gardenswartz |Simon Kaufman |Ava-joye Burnett

    President Donald Trump on Monday signed an executive order reviving a controversial plan to lower prescription drug costs by linking the price of certain medications in the U.S. to their lower prices in other countries. But the feasibility and impacts of Trump’s so-called “most favored nations" policy remain unclear, as some experts claim the order is unlikely to achieve what it promises and pharmaceutical groups consider legal challenges to it.

  • 3 weeks ago | scrippsnews.com | Jacob Gardenswartz |Simon Kaufman |Ava-joye Burnett

    President Donald Trump on Monday signed an executive order reviving a controversial plan to lower prescription drug costs by linking the price of certain medications in the U.S. to their lower prices in other countries. But the feasibility and impacts of Trump’s so-called “most favored nations" policy remain unclear, as some experts claim the order is unlikely to achieve what it promises and pharmaceutical groups consider legal challenges to it.

  • 3 weeks ago | tmj4.com | Jacob Gardenswartz |Simon Kaufman |Ava-joye Burnett |Tony Aria

    President Donald Trump on Monday signed an executive order reviving a controversial plan to lower prescription drug costs by linking the price of certain medications in the U.S. to their lower prices in other countries. But the feasibility and impacts of Trump’s so-called “most favored nations" policy remain unclear, as some experts claim the order is unlikely to achieve what it promises and pharmaceutical groups consider legal challenges to it.